Crinone Patent Expiration

Crinone is a drug owned by Allergan Sales Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 15, 2013. Details of Crinone's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5543150 Method of progesterone delivery and affect thereof
Sep, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Crinone is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Crinone's family patents as well as insights into ongoing legal events on those patents.

Crinone's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Crinone's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 15, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Crinone Generic API suppliers:

Progesterone is the generic name for the brand Crinone. 11 different companies have already filed for the generic of Crinone, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Crinone's generic

Alternative Brands for Crinone

Crinone which is used for hormonal support in women, such as in hormone replacement therapy or fertility treatments., has several other brand drugs using the same active ingredient (Progesterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Covis
Makena (autoinjector)
Ferring
Endometrin
Ferring Pharms Inc
Milprosa
Mayne Pharma
Bijuva
Pfizer
Depo-subq Provera 104
Wyeth Pharms
Premphase 14/14
Prempro


Apart from brand drugs containing the same ingredient, some generics have also been filed for Progesterone, Crinone's active ingredient. Check the complete list of approved generic manufacturers for Crinone





About Crinone

Crinone is a drug owned by Allergan Sales Llc. It is used for hormonal support in women, such as in hormone replacement therapy or fertility treatments. Crinone uses Progesterone as an active ingredient. Crinone was launched by Allergan in 1997.

Approval Date:

Crinone was approved by FDA for market use on 31 July, 1997.

Active Ingredient:

Crinone uses Progesterone as the active ingredient. Check out other Drugs and Companies using Progesterone ingredient

Treatment:

Crinone is used for hormonal support in women, such as in hormone replacement therapy or fertility treatments.

Dosage:

Crinone is available in gel form for vaginal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
4% GEL Prescription VAGINAL
8% GEL Prescription VAGINAL